(Q37872589)

24 August 2017

1 reference

title

Scraping fibrosis: expressway to the core of fibrosis (English)

1 reference

24 August 2017

Wajahat Z Mehal

1

1 reference

24 August 2017

John Iredale

series ordinal

2

1 reference

24 August 2017

Scott L Friedman

series ordinal

3

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 May 2011

1 reference

24 August 2017

1 reference

24 August 2017

17

1 reference

24 August 2017

5

1 reference

24 August 2017

552-553

1 reference

https://scigraph.springernature.com/pub.10.1038/nm0511-552

24 August 2017

0 references

cites work

Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3219752

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3219752

Cellular and molecular mechanisms of fibrosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3219752

Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3219752

Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3219752

Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3219752

Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3219752

The bone marrow functionally contributes to liver fibrosis.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3219752

Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3219752

Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3219752

Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3219752

Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing

1 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21546973

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NM0511-552

1 reference

24 August 2017

1 reference

24 August 2017

1 reference